The FDA notified the public of an increased risk of second primary malignancies in patients with newly-diagnosed multiple myeloma who received Revlimid (lenalidomide capsules; Celgene). This update is ...

Monjuvi, combined with Rituxan and Revlimid, extends progression-free survival to 22 months, reducing disease progression risk by over 50%. The inMIND trial's design and diverse patient population ...

Lupin has bagged the approval for Lenalidomide capsules. This drug is used in the treatment of Multiple Myeloma (MM). In an exchange filing, the company announced that it has received approval for its ...

Seattle's NanoString Technologies ($NSTG) stands to make up to $45 million if it can come up with a successful companion diagnostic test to screen for a subset of ...